journal
MENU ▼
Read by QxMD icon Read
search

Ecancermedicalscience

journal
https://www.readbyqxmd.com/read/27899957/next-generation-sequencing-in-nsclc-and-melanoma-patients-a-cost-and-budget-impact-analysis
#1
Rosa A van Amerongen, Valesca P Retèl, Veerle Mh Coupé, Petra M Nederlof, Maartje J Vogel, Wim H van Harten
Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the 'benefits' are not yet in relation to these costs. In this study, we give an estimation of the costs and an institutional and national budget impact of various types of NGS tests in non-small-cell lung cancer (NSCLC) and melanoma patients within The Netherlands...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899956/innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation
#2
W H van Harten, V P Retèl
With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899955/comparison-between-standard-and-reduced-volume-radiotherapy-in-bladder-preservation-trimodality-protocol-for-muscle-invasive-bladder-cancer-patients
#3
Waleed Arafat, Azza Darwish, George E Naoum, Wael Sameh, Gamal El Husseiny, Fathy Abd-El-Gawad, Mostafa Samir
AIM: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. MATERIAL AND METHOD: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB)...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899954/phosphoethanolamine-and-the-danger-of-unproven-drugs
#4
Noam Pondé, Evandro de Azambuja, Felipe Ades
The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent called phophoethanolamine (PHOS) has led to a widely publicized scientific scandal. PHOS is a precursor to components of the cell membrane, with some published pre-clinical studies suggesting cytotoxic activity in cancer cells. The willingness of courts and of legislators to guarantee access to PHOS in spite of the lack of any clinical data and against the recommendations of scientific and medical organisations underscores the risks that unproven agents pose to regulatory authorities, health care systems and patients, and bears resemblance to other cases such as the controversy surrounding the approval of zidovudine for AIDS treatment by the FDA...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899953/repurposing-drugs-in-oncology-redo-propranolol-as-an-anti-cancer-agent
#5
Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme
Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899952/prognostic-and-predictive-implications-of-sokal-euro-and-eutos-scores-in-chronic-myeloid-leukaemia-in-the-imatinib-era-experience-from-a-tertiary-oncology-centre-in-southern-india
#6
Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Govind Babu Kanakasetty, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Rajeev Krishnappa Lakkavalli, Lokesh N Kadabur, Rudresha Antapura Haleshappa
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder. Over the years many prognostic models have been developed to better risk stratify this disease at baseline. Sokal, Euro, and EUTOS scores were developed in varied populations initially receiving various therapies. Here we try to identify their predictive and prognostic implication in a larger population of Indian patients with CML-CP (chronic phase) in the imatinib era.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899951/the-first-case-of-benign-multicystic-mesothelioma-presenting-as-a-splenic-mass
#7
Antonio D'Antonio, Carlo Baldi, Maria Addesso, Carmine Napolitano
Multicystic mesothelioma (MM) is a relatively rare tumour arising in the pelvic peritoneum of the tuboovarian region of young woman. Exceptionally, MM occurs on the serosal surfaces of various organs including kidney, bladder, lymph nodes, and liver. We report here the first case of MM wherein a 58-year-old woman with a previous history of endometriosis of the right ovary presented with a large multicystic mass of the spleen. The diagnosis of MM was made on a surgical specimen after splenectomy. A histopathologic examination is always necessary for the diagnosis of MM which should be differentiated from other lesions particularly from cystic lymphangioma...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27729942/vero%C3%A2-radiotherapy-for-low-burden-cancer-789-patients-with-957-lesions
#8
R Orecchia, A Surgo, M Muto, A Ferrari, G Piperno, M A Gerardi, S Comi, C Garibaldi, D Ciardo, A Bazani, F Golino, F Pansini, C Fodor, P Romanelli, D Maestri, V Scroffi, S Mazza, B A Jereczek-Fossa
PURPOSE: The aim of this retrospective study is to evaluate patient profile, feasibility, and acute toxicity of RadioTherapy (RT) delivered by VERO® in the first 20 months of clinical activity. METHODS: Inclusion criteria: 1) adult patients; 2) limited volume cancer (M0 or oligometastatic); 3) small extracranial lesions; 4) treatment between April 2012 and December 2013 and 5) written informed consent. Two techniques were employed: intensity modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT)...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27729941/conditional-survival-of-metastatic-renal-cell-carcinoma-patients-treated-with-high-dose-interleukin-2
#9
David M Gill, David D Stenehjem, Kinjal Parikh, Joseph Merriman, Arun Sendilnathan, Archana M Agarwal, Andrew W Hahn, Sumati Gupta, Srinivas Kiran Tantravahi, Wolfram E Samlowski, Neeraj Agarwal
Conditional survival (CS) is a clinically useful prediction measure which adjusts a patient's prognosis based on their duration of survival since initiation of therapy. CS has been described in numerous malignancies, and recently described in patients with metastatic renal cell carcinoma (mRCC) who received vascular endothelial growth factor tyrosine kinase inhibitor (VEGFTKI) therapy. However, CS has been not reported in the context of mRCC treated with high-dose interleukin-2 therapy (HDIL-2). A total of 176 patients with histologically confirmed metastatic clear cell RCC (mccRCC) treated with HDIL-2 at the University of Utah Huntsman Cancer Institute from 1988-2012 were evaluated...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27729940/the-analytical-validation-of-the-oncotype-dx-recurrence-score-assay
#10
Frederick L Baehner
In vitro diagnostic multivariate index assays are highly complex molecular assays that can provide clinically actionable information regarding the underlying tumour biology and facilitate personalised treatment. These assays are only useful in clinical practice if all of the following are established: analytical validation (i.e., how accurately/reliably the assay measures the molecular characteristics), clinical validation (i.e., how consistently/accurately the test detects/predicts the outcomes of interest), and clinical utility (i...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27729939/is-blue-dye-still-required-during-sentinel-lymph-node-biopsy-for-breast-cancer
#11
Mirjam Cl Peek, Tibor Kovacs, Rose Baker, Hisham Hamed, Ash Kothari, Michael Douek
BACKGROUND: In early breast cancer, the optimal technique for sentinel lymph node biopsy (SLNB) is the combined technique (radioisotope and Patent Blue V) which achieves high identification rates. Despite this, many centres have decided to stop using blue dye due to blue-dye-related complications (tattoo, anaphylaxis). We evaluated the SLNB identification rate using the combined technique with and without Patent Blue V and the blue-dye-related complication rates. METHODS: Clinical and histological data were analysed on patients undergoing SLNB between March 2014 and April 2015...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610200/adoptive-cell-therapy-and-modulation-of-the-tumour-microenvironment-new-insights-from-asco-2016
#12
EDITORIAL
Leila Khoja, Bishal Gyawali
Immuno-oncology has changed the landscape of cancer treatment in recent years. Immune checkpoint inhibitors (ICI) have shown survival advantage with long term remissions in a variety of cancers. However, there is another approach to harnessing the power of the immune system in combating cancer: the adoptive cell therapy (ACT) strategy. Although ACT is restricted to small specialized centres and has yet to deliver as much success as ICI, some important results were presented at this year's ASCO meeting. Important lessons have been learned from these studies, including the prospects and challenges ahead...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610199/simple-trachelectomy-during-pregnancy-for-cervical-cancer
#13
Estefania Moreno-Luna, Patricia Alonso, Javier De Santiago, Ignacio Zapardiel
Invasive cervical cancer is rare during a pregnancy, even though it is one of the most frequently diagnosed neoplasias during that time. It is noted that around 30% of women diagnosed with cervical cancer are of reproductive age. This means that up to 3% of cases of cervical cancer are found in pregnant women or those who are in the post-birth period. A cervicovaginal Pap smear is performed as part of the regular checkup for a pregnant woman during the first visit so that cervical cancer can easily be diagnosed early in these women, detecting it early in up to 70-80% of cases...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610198/highlights-from-the-1st-latin-american-meeting-on-metronomic-chemotherapy-and-drug-repositioning-in-oncology-27-28-may-2016-rosario-argentina
#14
Adriana Rosé, Nicolas André, Viviana R Rozados, Leandro E Mainetti, Mauricio Menacho Márquez, María José Rico, Paula Schaiquevich, Milena Villarroel, Lauro Gregianin, Jaume Mora Graupera, Wendy Gómez García, Sidnei Epelman, Carlos Alasino, Daniel Alonso, Guillermo Chantada, O Graciela Scharovsky
Following previous metronomic meetings in Marseille (2011), Milano (2014), and Mumbai (2016), the first Latin American metronomic meeting was held in the School of Medical Sciences, National University of Rosario, Rosario, Argentina on 27 and 28 of May, 2016. For the first time, clinicians and researchers with experience in the field of metronomics, coming from different countries in Latin America, had the opportunity of presenting and discussing their work. The talks were organised in three main sessions related to experience in the pre-clinical, and clinical (paediatric and adult) areas...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610197/outcome-of-radical-prostatectomy-in-primary-circulating-prostate-cell-negative-prostate-cancer
#15
Nigel P Murray, Sócrates Aedo, Eduardo Reyes, Cynthia Fuentealba, Omar Jacob
INTRODUCTION: Around 90% of prostate cancers detected using the serum prostate specific antigen (PSA) as a screening test are considered to be localised. However, 20-30% of men treated by radical prostatectomy experience biochemical failure within two years of treatment. The presence of primary circulating prostate cells (CPCs) in the blood of these men implies a dissemination of the tumour and could indicate a greater risk of treatment failure. OBJECTIVE: To evaluate the use of the number of primary CPCs detected before surgery in the prediction of biochemical failure at ten years...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610196/maps-and-atlases-of-cancer-mortality-a-review-of-a-useful-tool-to-trigger-new-questions
#16
REVIEW
Alberto d'Onofrio, Chiara Mazzetta, Chris Robertson, Michel Smans, Peter Boyle, Mathieu Boniol
In this review we illustrate our view on the epidemiological relevance of geographically mapping cancer mortality. In the first part of this work, after delineating the history of cancer mapping with a view on interpretation of Cancer Mortality Atlases, we briefly illustrate the 'art' of cancer mapping. Later we summarise in a non-mathematical way basic methods of spatial statistics. In the second part of this paper, we employ the 'Atlas of Cancer Mortality in the European Union and the European Economic Area 1993-1997' in order to illustrate spatial aspects of cancer mortality in Europe...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610195/highlights-from-the-2016-win-symposium-27-29-june-2016-paris-personalised-therapy-beyond-next-generation-sequencing
#17
Richard Schilsky, Will Davies
The Worldwide Innovative Networking (WIN) consortium is an alliance of academic institutions, pharmaceutical partners, representatives from technology companies and charitable/health payer organisations from across the globe. For the last six years, the consortium's aims have been to foster communication and collaboration between members, encourage dialogue in an open forum, and deliver clinical trial results that improve the care and outcomes of patients with cancer using the latest advances in genomic-based medicine...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610194/small-cell-neuroendocrine-tumour-of-the-endometrium-and-the-importance-of-pathologic-diagnosis
#18
Adriana Estruch, Lucas Minig, Carmen Illueca, Ignacio Romero, Jose Luis Guinot, Andrés Poveda
Small cell carcinoma of the endometrium is a very rare entity. They are very aggressive tumours, with a poor prognosis. They represent a clinical challenge because of a lack of a standardised treatment. We see here a case of a 67-year-old woman with a history of a lobular breast carcinoma, diagnosed in 2002. After presenting with postmenopausal vaginal bleeding in October 2014, she underwent a hysteroscopy-guided biopsy which revealed a metastasis of breast carcinoma. A hysterectomy and bilateral oophorectomy was performed because of uncontrolled uterine bleeding...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27610193/children-s-palliative-care-now-highlights-from-the-second-icpcn-conference-on-children-s-palliative-care-18-21-may-2016-buenos-aires-argentina
#19
J Downing, R Kiman, S Boucher, B Nkosi, B Steel, C Marston, E Lascar, J Marston
The International Children's Palliative Care Network held its second international conference on children's palliative care in Buenos Aires, Argentina, from the 18th-21st May 2016. The theme of the conference was 'Children's Palliative Care…. Now!' emphasising the need for palliative care for children now, as the future will be too late for many of them. Six pre-conference workshops were held, addressing issues connected to pain assessment and management, adolescent palliative care, ethics and decision-making, developing programmes, the basics of children's palliative care, and hidden aspects of children's palliative care...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27594913/negative-trials-in-ovarian-cancer-is-there-such-a-thing-as-too-much-optimism
#20
EDITORIAL
Bishal Gyawali, Vinay Prasad
Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal...
2016: Ecancermedicalscience
journal
journal
41838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"